taken
culated
london
pyrimeth
alleles
458
medicine
shown
threshold
excluded
trust
boende
super
curves
contributions
balkan
prim
malar
address
crest
dq
tieres
project
sided
estimate
loretxu
2002
death
proof
meier
yambe
appropriate
rate
tables
ran
recurrence
bukirwa4
bonnet
conditions
treated
source
pukrittayakamee
outcome
allowing
ear
smithuis
573
suspicion
whom
mshinda
even
ltd
eaa
eligible
keppel
immediately
acceptance
ance
artemether
serious
collabora
ratories
keep
tororo
yours
genotyped
final
cohuet
subsequent
discrepancies
kilian
drugs
arms
denoncin
rent
sabin
table
lcfs
bal
kindamba
references
n'zerekore
country
tial
dunand
met
tt
white
could
rates
fortes
saint
referred
coordination
cv
research
frxqw
eliminated
sion
hopital
facilitate
both
disseminating
icy
1950
licensee
rt
decisions
dioulasso
coulibaly
trop
analysable
would
wrongly
administered
day14
deploy
get
pablo
335
recommendation
pleted
kenya
guerin
disease
underwent
kiguli
hanoi
fulwhuld
anal
genetics
approach
efficacy
parasitae
smear
prevention
grateful
rather
closely
age
mann
recommended
higher
draft
tests
van
results
late
valid
antimalarial
wkdq
likelihood
pared
overestima
appear
area
sb
chemother
paring
funding
refugee
pota
stating
four
zation
209
recommendations
bobtaylor
orig
affected
drc
individual
entire
who
represented
previously
snounou
featured
11oxford
laboratories
database
sdudvlwrorjlfdo
3096
luuhvshfwlyh
failure
commonly
calculate
filomeno
pre
piero
studies
broek5
franco
chloroquine
ci95
580
1257
author
utility
act
college
enabling
provide
way
139
categorized
classifying
swarthout
universities
fol
implications
san
imported
1972
individ
losses
patient
programmatic
presented
adequately
2926
gabriel
description
populations
113
gmail
msf
kemri
alone
little
correctly
combination
bie
talisuna
tended
inves
ringwald
combina
rules
otyping
regimen
fied
original
nonartemisi
increase
soc
absolute
wkh
doi
2001
published
tive
possible
months
widely
chem
later
kept
derivative
hp
members
length
imt
6center
cost
urruta8
proportions
excluding
under
bobigny
hygiene
nsobya
498
molecular
ingrid
inas
our
its
earlier
determined
francesco
vised
utable
ch
5oc
deployed
accepted
635
medical
genomics
vomiting
iz
end
3103
msp2
failures
particular
classified
sdudvlwdhpld
without
than
wald
fever
just
department
lam
reduction
tional
traditional
14centre
follow
vanherp
day28
resistance
shaded
methodology
consent
stud
practice
order
bio
following
data
jean
hagerman
underestimated
predictably
after
amodiaquine
as
permitted
rivm
growing
difference
atkin
belgium
guth
variables
assessment
kamya
vietnam
unicef
overestimated
document
new
shoklo
evaluation
org
entirely
reviewed
mum
kayembe
respectively
develop
stepniewska
vaccinology
acpr
classifications
min
draogo
conclusion
376
ner
cited
your
parasitaemic
hy
differ
generated
special
criteria
describe
changed
censoring
gen
antwerp
eight
cousens
compared
nuffield
ashley
combinations
did
sidered
recrudescences
method
herp9
any
cision
inal
caala
more
subjects
hien
mini
suhylrxvo
prophylactic
regarding
kaplan
mono
report
authorities
detailed
most
col
greenhouse
had
migration
dataset
noel
parative
roper
fc
mountains
kin
gdorsey
again
nership
relevant
fron
analyt
much
institut
explained
part
suhvhqfh
rescue
iii
naidoo
assessing
lifetime
seen
drug
upon
only
frontieres
706
involuntary
recorded
multisite
unclassifiable
remainder
analyses
119
biomed
publishing_adv
fal
malarial
meet
into
gm
good
making
systematic
cleared
netnam
tal
violation
associated
dqg
205
sanitaire
7lj
uganda
increasing
recrudescence
least
pharmacie
depending
percentage
analysis
tinto
ouedraogo
straightaway
overestimation
received
last
kampala
panying
notes
update
todd
overview
biomedcentral
faso
mr
anti
balkan10
august
msp1
ministries
ntoumi
individuals
glutamate
some
applied
1511
oucru
bosco
parentheses
unrestricted
techniques
non
aquine
against
regarded
sis
vljqv
failing
needs
missing
provinces
tolerability
adherence
censored
infectious
likely
shorter
burkina
glo
e190
necessarily
adjustment
tobback
accurate
com
france
chloro
intense
cent
churchill
des
creative
maladies
1359
enrolment
parasitol
loci
product
maryline
saharan
glurp
course
lower
presse
follows
design
2794
lq
zongo_issaka
interests
becomes
1928
concept
et
switzerland
occurred
involved
pj
other
corrected
vaillant
tations
sul
limi
licenses
oxford
francis
4271
university
pecoulas
treatmentguidelines2006
rences
herp
reap
another
genotypes
view
rq
wellcome
maheba
2008
clinically
merged
opinion
cured
guide
sally
failur
walter
reports
plowe
choice
well
beck
recent
genotyp
dorsey
institutes
potential
newer
retains
reappearance
phhwlqj
olliaro
sources
none
kabalo
followed
acts
gillet
divided
barnes
pcr
mufuta
world
hospital
uncorrected
early
ers
databases
yses
118
para
1021
precision
figure
unresolved
being
december
polymerase
val
pubmed
5medecins
ba
copyright
548
http
rouamba
pdf
leads
may
archived
different
terms
definitions
364
consensus
tigators
sg
pedro
summarized
infec
uncompli
number
int
ea
adjuik
organization
lumefantrine
mpimbaza
population
test
dorsey2
lp
resist
100
how
identical
their
nurse
therefore
slowly
included
asymptomatic
interpretation
yeka
required
makes
also
guthmann1
distribution
related
cancer
consultation
but
over
cedex
prevent
documented
ucsf
analy
evhqfh
statistical
ranged
citation
especially
include
papers
evidence
jc
2875
hasifa
ghabri
allows
500
sir
based
banek
adoke
comparisons
illustrates
rue
eatment
unit
made
page
evelyn
4280
sam
febrile
such
greater
826
current
comitant
hduo
amsterdam
assessed
combining
member
wabwire
programme
dealt
time
evaluate
ri
ment
convenience
mic
melaku
human
medecins
rated
tropicale
cal
parasitolog
indeterminate
wj
nine
trivial
represent
has
reaction
2007
isuna
nzarubara
reason
labo
veille
ples
kljkhu
days
hypersensitivity
boxes
sdwlhqw
grant
sufficiently
dabola
143
trends
violations
use
jpg
markedly
effi
518
1211
slater
idloxuh
3720
uncomplicated
approaches
temperature
weighted
box
staedke
therapy
views
con
lpf
mentioned
charge
hyperen
3739
durand
facility
nin
replace
randomized
observed
texas
ivdb
surveillance
1475
ducted
edu
np
range
collins
medium
contentious
particularly
effect
transmission
166
broek
esponse
abstract
major
issues
2662
primary
acknowledgements
salah
falci
combined
rand
sp
ki
127
monotherapy
lowing
trans
email
rative
1epicentre
withdrawal
lysing
to21
previous
recurrent
verified
prince
reduce
studied
access
figures
land
kironde
activity
presence
ehwzhhq
thank
naawa
there
gd
to19
regardless
larial
thailand
montgomery
quinine
maurice
falciparum
certain
occur
mosquito
info
medsfgh
meeting
varying
amount
recru
departement
occurs
confirmed
inter
authors
price
researc
african
should
zongo
domised
parum
calculated
selected
pol
interest
barcelona
dur
therapies
clinical
treatments
properly
undetected
settlement
phadoxine
defini
proposed
differences
vivo
underestimation
biomedical
reporting
objectives
inferiority
line
bakyaita
result
recurrences
findings
quine
plus
need
esti
grandesso
per
performed
angola
d'osne
trials
reinfections
powered
difficult
deviations
distinguishing
plied
zlwk
period
important
samples
presents
martine
all
amudat
2006
arua
depoortere
kailahun
lpfs
total
development
support
submit
maximizes
parasite
154
including
control
endpoints
sciences
wr
february
complete
1957
554
content
malaria
artemisinin
sibley
wrote
kan
negative
1350
essen
pretation
oratory
below
during
centers
multiple
cases
rosenthal
amplified
methods
guiguemde
duration
reingold
moses
revised
execution
environment
distributed
sus
1186
attribution
open
significant
magnitude
participated
8medecins
inclusion
designed
extraction
post
biggest
ford
pooled
cacy
efficacious
they
definition
micheli
popula
117
successes
clinic
annex
according
wuhdwphqw
preserves
lfu
recherche
suggest
staff
taylor11
plos
withdrawals
main
classification
antima
491
2871
alternative
distinguish
protein
accom
date
median
unacceptable
folqlfdo
life
subject
damba
symptoms
crista
legros
every
enrolled
wambugu
appears
national
policy
145
sulfadoxine
risk
algorithms
1015
permits
highly
measured
strictly
bukirwa
study
yahoo
arm
cis
epicentre
guthmann
declines
outcomes
lected
visit
california
kasia
case
respon
10medecins
surface
sites
120
defined
taylor
amine
vaccinale
overmeir
jp
pascal
200
monitoring
kamara
advised
omized
investigators
varied
clas
democratic
competing
resolved
bilthoven
avicenne
impact
formulation
examine
smru
reappeared
mia
turyakira1
standardi
med
conceived
lankoande
amodi
pyrimethamine
provided
lcf
large
sense
relatively
2department
mangen
methodological
treatment
excel
accuracy
commons
hyg
become
initial
monitored
apac
central
history
tion
ciparum
attrib
classi
several
huambo
3dudvlwhv
assistance
varia
lead
comparable
baseline
sierra
leone
kuito
1503
maximal
prevailing
treat
whose
par
corresponding
discussion
2005
jb
second
parasitologically
sulphadoxine
versus
reported
rence
randomised
kankolongo
work
recur
mugittu
conducted
nuba
hubbard
mk
ways
whether
pro
three
464
reference
inaccurate
pdoduld
was
two
each
descence
asitological
africa
checchi
assess
technique
elizabeth
evolve
tropical
participants
countries
identification
half
jinja
limit
available
ox3
approved
however
selections
demic
patients
determinant
loodu
one
brief
estimated
merozoite
site
saraiva
year
usa
paris
laboratory
pearance
challeng
standardized
among
considered
1702
ies
microsatellites
ical
proportion
reasons
undp
acprs
genotype
still
will
infected
684
parasitaemia
average
network
sample
classify
infection
genotyping
9medecins
unexpected
recoded
dqjhu
drawals
nosten
numbers
h_bukirwa
journal
dujardin
markers
tdr
netherlands
734
parasitological
kitz
ring
3uhvhqfh
sans
hook
recurr
recrudes
antimicrob
weeks
bases
ci
formula
due
consequent
scollo
muhendo
reclassified
increased
six
mulemba
quality
intensity
creativecommons
replacement
thus
similar
1995
francisco
evaluated
changes
areas
precise
described
indicate
same
free
fac
rich
standardize
license
explanation
haplotypes
others
ru
zongo7
here
lancet
ecommendation
ver
balasegaram
den
expressed
given
palma
aged
congo
sudan
chain
medecine
sible
principal
zambia
article
blantyre
between
832
peer
determining
gramme
fail
expert
guinea
865
enable
extract
farrar
trial
sipilan
issaka
td
publication
genotypic
www
adequate
ysis
controlled
12travel
public
diseases
programmes
entry
taking
children
day
determination
stata
agents
ampuero
brussels
performing
parasites
scientist
illness
geneva
1967
using
single
since
critical
debatable
d14
1996
ing
dna
ever
122
libama
standardization
fred
upper
amplify
olliaro13
sity
lost
odwh
corp
clearance
nj
manuscript
plasmodium
sipilanyambe
exceeded
tinue
suna
within
obtained
rouen
reinfection
led
points
declare
2004
702
leopold
response
because
depends
13unicef
spain
bank
level
mayxay
resistant
nkandu
concomitant
occurring
uk
done
michel
infections
makers
urruta
management
transmis
guidelines
219
3734
whpshudwxuh
collabo
looareesuwan
vary
zlwkrxw
survival
docs
mvh
ual
them
optimal
bk
used
myint
true
ihyhu
users
mated
considerable
drug's
olliarop
when
background
lab
felix
gaboulaud
incorporating
efforts
valerie
1090
94415
vhyhuh
exclusion
hence
15unite
ltf
invs
485
caregivers
debate
hamour
further
change
summary
institute
typing
considerations
unknown
tors
point
minority
hand
4uganda
performance
sophie
overestimate
hb
aq
000
analytical
small
therapeutic
duced
turyakira
wrt
3london
repeated
laufer
sante
training
low
allele
369
rn
while
modification
paul
developed
purposes
to24
irrespective
imum
school
pl
rigutto
pe
tions
bobo
read
3dudvlwdhpld
purpose
1965
present
republic
infectieuses
dokomajilar
mbarara
analysed
susceptibility
492
d'alessandro
baird
rwakimari
common
either
health
simplicity
7institut
review
lshtm
geno
comparing
ana
interpreted
general
maximum
sified
75011
five
regimens
1017
artesunate
attas
cated
etf
list
out
al
modified
oratories
falls
core
ppp
smallest
size
estimates
discriminatory
categories
publish
sandra
pinoges1
ure
helped
designs
priotto
tradi
switzer
pinoges
942
majority
eleanor
kyo
existing
protocol
ethical
endpoint
asp
intro
oue
avoids
keus
223
malawi
noted
sl
highest
malariajournal
jk
reproduction
cannot
not
years
loss
po
effectiveness
remain
checchi3
severe
reduced
times
standard
faculte
community
recrudescent
before
success
team
high
anne
modifications
first
sub
2003